Background: The amplified in breast cancer 1 (AIB1) gene has been considered to play an oncogenic role in human cancers, but its clinical/prognostic significance in non-small-cell lung cancer (NSCLC) is still unclear.
introduction
Lung cancer is responsible for the highest cancer-related morbidity and mortality worldwide [1] . Non-small-cell lung cancer (NSCLC), which accounts for 85%-87% of all lung cancers, is a very heterogenous group of malignancies as far as the pathomorphology, local invasion and metastatic potential are concerned [2] . Clinically, the international lung cancer staging system is still not reliable enough to predict patient prognosis. The most possibly underlying reason might be the heterogeneous biological properties of NSCLC. Therefore, the search for specific genes alterations, which determine biological nature and behavior of NSCLC would be of utmost importance to optimize individual therapy [3] .
It is conceivable that amplified DNA may be a component of one or more critical human oncogenes and thus may provide a selective advantage for tumor development. One of the commonly overrepresented chromosomal regions in NSCLC is 20q [4] . Several candidate oncogenes have been isolated from 20q, including amplified in breast cancer 1 (AIB1) at 20q12. The AIB1 gene, also known as SRC-3, p/CIP, RAC3, ACTR and TRAM-1, has been found to be involved in a number of biological processes, such as cell proliferation, cell apoptosis, cell migration and others [5] . The oncogenic role of AIB1 was first reported in hormone-sensitive cancers [6] , and then, we contiguously reported that AIB1 was also overexpressed and correlated closely with an ascending clinical stage and/or poor patient prognosis in a series of hormone-insensitive malignancies [7] [8] [9] [10] [11] . Recently, AIB1 was found to express variably among different types of human NSCLC cells [12] . However, the abnormalities of AIB1 in NSCLC and its clinical/ prognostic significance have not been determined. In this study, immunohistochemistry (IHC) and FISH were used to examine protein expression and amplification of AIB1 in a large cohort of surgically resected NSCLC, and the clinicopathologic/ prognostic significance of AIB1 expression in NSCLC was also assessed.
patients and methods patients
In this study, 248 NSCLC patients who received complete resection in Thoracic Department of Cancer Center, Sun Yat-sen University, Guangzhou, China, from February 1994 to January 1998 were enrolled. The cases were selected consecutively on the basis of availability of resection tissue and follow-up data. Patients who have previous malignant disease, a second primary tumor or those who received preoperative radiotherapy and/or chemotherapy were excluded. In the majority of cases, lobectomy was carried out (223 of 248 patients) and 25 patients underwent pneumonectomy. Because adjuvant chemotherapy become a standard approach only after 2004, systemic chemotherapy using cisplatin-based combinations was administered to patients with stages III NSCLCs, no postoperative therapy was delivered to patients in stage I-II. Patients with stage III disease and pathologic evidence of N2 disease received postoperative mediastinal radiotherapy.
The study was approved by the medical ethics committee of Cancer Center of Sun Yat-Sen University. Tumor differentiation grades were defined according to the criteria of the World Health Organization. The pathologic tumor-node-metastasis (pTNM) status of all NSCLCs was assessed according to the criteria of the sixth edition of the TNM classification of the International Union Against Cancer (2002). The clinicopathologic features of the NSCLC cohort are outlined in Table 1 . All the patients were followed up regularly and the last follow-up was carried out in December 2008, with the mean observation period of 65.3 months (3.2-172.5 months) and 167 cancer-related deaths.
construction of tissue microarrays
The tissue microarray (TMA) was constructed according to a method described previously [13] . Briefly, the individual donor tissue block and the corresponding histological hematoxylin-eosin stained slides were overlaid for tissue TMA sampling. The tissues (248 NSCLC and 30 normal lung tissues taken from regions that were not affected of the same patients) were sampled using a tissue arraying instrument (Beecher Instruments, Silver Spring, MD); a 0.6-mm-diameter cylinder of tissue was removed. Subsequently, the tissue cylinder was re-embedded into a predetermined position in a recipient paraffin block. In our constructed lung tissue TMA, three cores of sample were selected from each primary NSCLC and normal lung tissue. Multiple sections (5 lm thick) were cut from the TMA block and mounted on microscope slides. [Clone MIB-1 (Dako), diluted 1 : 100 in PBS, overnight at 4°C]. All incubations were carried out in a moist chamber. Subsequently, the slides were sequentially incubated with biotinylated rabbit anti-mouse immunoglobulin (Ig) at a concentration of 1 : 100 for 30 min at 37°C and then reacted with a streptavidin-peroxidase conjugate for 30 min at 37°C and 3#,3#-Diaminobenzidine as a chromogen substrate. The nucleus was counterstained using Meyer's hematoxylin. Known immunostaining positive slides of breast cancer (AIB1, ER-a, ER-b and PgR) and prostate cancer (AR) were used as positive controls. A negative control was obtained by replacing the primary antibody with a normal murine IgG.
Positive expression of AIB1 in normal and malignant lung tissues was primarily a nuclear pattern ( Figure 1 ). For AIB1, the staining of the nuclei of the normal lung tissues ranged from 0% to 10% (median 2.3%) of epithelium with positive staining ( Figure 1A and B); thus, overexpression of AIB1 was scored when >10% of tumor cells were positively stained in the nuclei [8] [9] [10] [11] . For evaluation of the AIB1, ER, PgR, AR and Ki-67 IHC staining in the different tissue sections, the cancerous and noncancerous tissues were scored for these proteins by assessing the site of positive staining in the nucleus. The status of nuclear expression of AIB1, ER, PgR, [11, 14] . A minimum of 300 epithelial cells was counted for each case.
FISH
Two-color FISH was applied to the sections of TMA using spectrum orange-labeled bacterial artificial chromosome (BAC) clone (RP11-447G11) containing the AIB1 gene and a spectrum green-labeled BAC clone on 20p12 (reference probe). The FISH reaction was carried out as described previously with slight modification [8] . Briefly, the deparaffinized TMA section was treated with proteinase K (400 lg/ml) at 37°C for 45 min, followed by denaturing in 70% formamide, 2· standard saline citrate (SSC) at 75°C for 8 min. Fifty nanograms of each probe were mixed in a 20 ll hybridization mixture (containing 55% formamide, 2· SSC, and 2 lg human Cot1 DNA), denatured at 75°C for 5 min and then hybridized to the denatured TMA section at 37°C for 24 h. After washing, the TMA section was counterstained with 1 lg/ml diamidino-phenyl-indole in an antifade solution and examined with a Zeiss Axiophot microscope equipped with a triple-band-pass filter. FISH signals from 300 cells in each sample were counted. The criteria for AIB1 gene amplification were defined as the presence (in ‡20% of tumor cells) of either six (or more) gene signals or >2.5 times as many gene signals than reference 20p11 signals ( Figure 1F ) [11] . All samples not meeting the criteria for gain or amplification were considered normal. Control hybridizations to normal fibroblasts and to normal epithelial cells were carried out to confirm that the hybridization efficiency of the test and reference probes was similar. Two independent pathologists (XD and Rao HL) blinded to the clinicopathologic information carried out the scorings. The interobserver disagreements (8% and 3% of the total informative cases for IHC and FISH, respectively) were reviewed a second time, followed by a conclusive judgment by both pathologists.
statistical analysis
Statistical analysis was carried out with the SPSS software (SPSS standard version 13.0; SPSS Inc., Chicago, IL). The association of AIB1 protein expression with NSCLC patient's clinicopathologic features and the correlations between molecular features detected with each other were assessed by the chi-square test. Disease-specific survival (DSS) was calculated from the date of diagnosis to the date of cancer-related death or last follow-up. Relative risks of cancer-related death associated with AIB1 expression status and other predictor variables were estimated from univariate Cox proportional hazards model. Multivariate survival analysis was carried out on all parameters that were found to be significant on univariate analysis using the Cox regression model. Survival curves were assessed by the Kaplan-Meier method and compared by the log-rank test. Two-sided P values of <0.05 were considered to indicate statistical significance.
results

AIB1 expression in NSCLC and normal lung tissues
AIB1 expression could be evaluated informatively in 230 of 248 (92.7%) of the NSCLCs and 26 of 30 (86.7%) of normal lung tissues. The noninformative samples included unrepresentative samples, samples with too few tumor cells (<300 cells per case) and lost samples; such were not used in data compilation. Using this criteria described above, overexpression of AIB1 was observed in 111 of 230 (48.3%) of the NSCLCs and correlated with an ascending pathologic node (pN) stage for lung adenocarcinoma (ADC) but not for squamous cell carcinoma (SCC) ( Table 1) .
relationship between clinicopathologic variables, AIB1 expression and NSCLC patient survival
In univariate analysis, AIB1 overexpression was evaluated to correlate closely with poor DSS for the whole cohort and could further stratify patient survival in SCC, ADC, pT3/4, pN1/2 and III stages ( Figure 2 ; Table 2 ). Kaplan-Meier analysis also demonstrated a significant impact of certain clinicopathologic prognostic parameters such as tumor pT status (P = 0.013), pN status (P < 0.001) and clinical stage (P < 0.001) on patient survival. Multivariate analysis showed that AIB1 expression and pN status were independent predictors of DSS for the whole cohort (Table 3 ). In our NSCLC cohorts, the median value of 25.6% was used as a cut-off value to define low Ki-67 labeling index (LI) (LI <25.6%) and high Ki-67 LI (LI ‡25.6%) [9, 10] . In 212 of the 248 samples, AIB1 and Ki-67 IHC were detected successfully and simultaneously. Correlation analysis demonstrates that the frequency of cases with a high LI of Ki-67 was significantly greater in tumors with an overexpression of AIB1 (54 of 77, 70.1%) than that in cases with normal expression of AIB1 (23 of 77, 29.9%; P < 0.001).
amplification of AIB1 in NSCLC and normal lung tissues
The FISH analysis was informative in 53.3% (16 of 30) of the normal lung tissues and 54.0% (134 of 248) of the NCSLCs. Samples without FISH signal and samples with weak target signals or those with a strong signal background were the main reasons for most of the noninformative cases. The amplification of AIB1 was not detected in any of the normal lung tissues but was observed in 8.2% (11 of 134) of the informative NCSLCs. In our study, 121 informative cases were shown to be positive by both IHC and FISH simultaneously, and a significant correlation between AIB1 overexpression and amplification of AIB1 was found (Table 4) .
discussion
In the present study, we found that the expression of AIB1 by IHC in all the normal lung tissue specimens was absent or at low levels. In contrast, in many of our NSCLC specimens, an overexpression of AIB1 was frequently detected, which indicated a potential important role of AIB1 in carcinogenesis of lung. Similar results were also observed in other human cancers, such as esophageal, gastric, colorectal and nasopharyngeal carcinomas, in which up-regulating of AIB1 was observed and correlated with a late clinical stage and/or poor prognosis [9, 10, 15] . It is well known that the pathogenesis and biologic behaviors of different subtypes of NSCLC are quite distinct. The underline mechanism might contribute, at least partly to the molecular diversity. Although no significant association was found between AIB1 expression and clinicopathologic features for the whole cohort, interestingly, a steady increase of AIB1 expression was observed in ADCs of lung from no lymph node metastasis to peribronchial lymph node metastasis and to mediastinal lymph node metastasis. These findings indicated that up-regulated expression of AIB1 may provide a selective advantage in lymph AIB1, amplified in breast cancer 1; NSCLC, non-small-cell lung carcinoma; SCC, squamous cell carcinoma; ADC, adenocarcinoma; pT, pathologic tumor; pN, pathologic node. node metastasis of lung ADC. Since the sensitivity and specificity of computed tomography scans for the detection of mediastinal lymph nodes metastasis are only 70% [16] , and the existence of lymph node metastasis seriously affects the prognosis of lung cancer, therefore, the expression status of AIB1, as detected by IHC, might be helpful in making accurate staging essential in the selection of a treatment plan for lung ADC patients. Most importantly, AIB1 expression was evaluated as the most significant prognostic factor in multivariate Cox regression analysis, which indicated an important role of AIB1 in the progression process of NSCLC. Furthermore, AIB1 expression could stratify patient survival in pT3/4, pN1/2 and III stages. As we know, surgical resection is the most effective method to control localized NSCLCs, and however, it might be insufficient for locally advanced cases, as inferred from 80% death within 5 years after single modality of surgery [17] ; thus, adjuvant or neoadjuvant treatment are actually needed [18] . Although recent studies indicate that multimodality approaches are effective in the treatment of stage III disease, however, such therapies might account for higher mortality in certain subsets of patients [19] . Our results indicated that locally advanced NSCLC patients who have AIB1 overexpression would present with shorter survival time after surgery compared with those who have AIB1 expression, which might provide some information in identifying the patients who actually need and might benefit from the multimodality therapies, thus optimize individual therapeutic management. One of the limitations of this study is that the results of the subgroup analyses were on the basis of relatively small sample size in some subsets of patients. Thus, a larger scale, multicenter study is needed to confirm these results.
It is well established that an increase in copy number of an oncogene, due to amplification, in human cancer, often produces an excess of encoded protein. To determine whether the overexpression of AIB1 in our NSCLC series was caused by gene amplification, the copy number of AIB1 was examined by FISH. We observed that overexpression of AIB1 was associated but not always coincided with AIB1 gene amplification. Similar results were also found in breast, colorectal, gastric, esophageal and bladder cancers [8, 9, 11, 15, 20] . These results indicate that the mechanisms of regulation of AIB1 expression are complicated. Recently, AIB1 was found to be self-regulated at transcription levels [21] . Moreover, it has been demonstrated that translation of AIB1 messenger RNA (mRNA) can be regulated by endogenous microRNAs [22] , and the AIB1 protein levels are also influenced by proteasomal degradation pathways [23] . In addition, several cytokines, e.g. inhibitor of nuclear factor-kappa B kinase and transforming growth factorb, were also involved in the regulation of AIB1 expression [24, 25] . These results indicated that, in addition to gene amplification, the modification of AIB1 expression could also be regulated by many other mechanisms, such as transcription levels, mRNA stability and post-translational modification.
With respect to the function of the AIB1 gene, it has been recognized as a member of the p160 family and a coactivator for nuclear hormone receptors including ER, PgR and AR [6] . Meanwhile, AIB1 was found to frequently amplify and overexpress in a number of hormone-sensitive human tumors [26, 27] , which indicates that AIB1 may play a role in tumorigenesis of specific subsets of hormone-sensitive cancers, perhaps by facilitating hormone-dependent signal transduction pathways. Interestingly, overexpression of AIB1 was detected in breast tumors positive and negative for ER and PgR [28] , while AIB1 knockdown impaired the proliferation of both ARpositive and AR-negative prostate cancer cells [27] . In human lung cancer, it has been reported that estrogen-signaling pathway (including AIB1) plays an important role in NSCLC carcinogenesis [12] . Consistent with previous findings [14, 29] , ER-a, ER-b and PgR were detected in significant proportions of our NSCLC specimens. However, no significant correlations were observed between the expression of AIB1 and ER or PgR, and none of our NSCLC cases showed IHC-positive staining for AR. These results indicated there might be some hormoneindependent mechanisms exist in the tumorigenesis process of NSCLC. Recently, extensive investigations revealed that AIB1 can interact with a broad spectrum of transcription factors in addition to hormone receptors, and AIB1 also was found to be involved in many non-hormone responsive tumors [5, 6] . In our study, we found a strong positive association of AIB1 overexpression and high cell proliferation in NSCLCs, which might be responsible, at least in part, for NSCLC tumorigenesis and/or progression. Clearly, further work needs to be done to determine the precise signaling pathway of AIB1 that is ultimately involved in the pathogenesis of NSCLC.
In summary, our results provide some evidence for the concept that (i) overexpression of AIB1 might provide a selective advantage for lymph node metastasis of lung ADC and (ii) AIB1 plays an adverse role in the prognosis of NSCLC, especially for those with locally advanced disease, which might be helpful to optimize individual therapy management. 
